Want to see BLLN full AI Analyst Report?
BLLN Stock Chart & Stats
$100.08
-$0.81(-0.83%)
At close: 4:00 PM EDT
$100.08
-$0.81(-0.83%)
Day’s Range― - ―
52-Week Range$61.96 - $150.44
Previous Close$98
Volume370.05K
Average Volume (3M)678.97K
Market Cap
$4.56B
Enterprise Value$6.13K
Total Cash (Recent Filing)$548.63M
Total Debt (Recent Filing)$143.92M
Price to Earnings (P/E)140.2
Beta0.07
Next Earnings
Dec 15, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.69
Shares Outstanding42,644,386
10 Day Avg. Volume580,370
30 Day Avg. Volume678,966
Financial Highlights & Ratios
PEG Ratio-12.02
Price to Book (P/B)7.81
Price to Sales (P/S)12.29
P/FCF Ratio238.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$123.33Price Target Upside23.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.81
Revenue Forecast (FY)$456.05M
Bulls Say, Bears Say
Bulls Say
Revenue And Volume GrowthSustained high revenue and test-volume growth signal durable commercial traction across prenatal and oncology lines. Faster volume and ASP expansion indicate product-market fit and scalable demand, supporting multi-quarter revenue visibility and the company’s ability to leverage fixed lab costs.
High Gross MarginsConsistently elevated gross margins reflect differentiated smNGS technology and favorable unit economics. High QC reliability and low failure rates reduce waste and rework, enabling margin sustainability as volumes scale and partially insulating profitability from pricing pressure over multiple quarters.
De-risked Balance SheetMarked reduction in leverage and a larger equity base, together with recent positive free cash flow and a sizable cash balance, materially increase financial flexibility. This supports continued investment in commercial scale and lab capacity without immediate refinancing risk.
Bears Say
Thin Net Margins / Low ROEAlthough profitability has turned positive, margins and returns remain modest; a ~2% net margin and low ROE imply limited buffer against cost increases or slower-than-expected revenue growth. Sustained improvement requires continued operating leverage and disciplined opex management.
True-up Revenue VolatilityMaterial swings in true-up recognition create forecasting uncertainty and can distort quarter-to-quarter margins and cash timing. Reliance on episodic true-up receipts reduces predictability of revenue and complicates near-term planning for capacity and working capital.
Payer & Coverage Execution RiskSignificant held claims and pending MolDX Medicare coverage create execution risk for realized ASPs and cash collections. Delays or unfavorable reimbursement outcomes could compress realized revenues and slow oncology unit economics improvement despite strong clinical data.
BillionToOne, Inc. Class A News
BLLN FAQ
What was BillionToOne, Inc. Class A’s price range in the past 12 months?
BillionToOne, Inc. Class A lowest stock price was $61.96 and its highest was $150.44 in the past 12 months.
What is BillionToOne, Inc. Class A’s market cap?
BillionToOne, Inc. Class A’s market cap is $4.56B.
When is BillionToOne, Inc. Class A’s upcoming earnings report date?
BillionToOne, Inc. Class A’s upcoming earnings report date is Dec 15, 2026 which is in 111 days.
How were BillionToOne, Inc. Class A’s earnings last quarter?
BillionToOne, Inc. Class A released its earnings results on Aug 05, 2026. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.183 by -$0.033.
Is BillionToOne, Inc. Class A overvalued?
According to Wall Street analysts BillionToOne, Inc. Class A’s price is currently Undervalued.
Does BillionToOne, Inc. Class A pay dividends?
BillionToOne, Inc. Class A does not currently pay dividends.
What is BillionToOne, Inc. Class A’s EPS estimate?
BillionToOne, Inc. Class A’s EPS estimate is 0.15.
How many shares outstanding does BillionToOne, Inc. Class A have?
BillionToOne, Inc. Class A has 42,644,386 shares outstanding.
What happened to BillionToOne, Inc. Class A’s price movement after its last earnings report?
BillionToOne, Inc. Class A reported an EPS of $0.15 in its last earnings report, missing expectations of $0.183. Following the earnings report the stock price went down -38.888%.
Which hedge fund is a major shareholder of BillionToOne, Inc. Class A?
Currently, no hedge funds are holding shares in BLLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BillionToOne, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$123.33 (23.23% Upside)
$123.33 (23.23% Upside)
Blogger Sentiment
Bullish
BLLN Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 19.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $944.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 19.1%
Last 30 Days ▲ 19.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
133.40%
Trailing 12-Months
Company Description
BillionToOne, Inc. Class A
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
BLLN Company Deck
BLLN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a predominantly positive operational and financial picture: strong year-over-year revenue growth (64%), rapid test volume expansion (35%), material oncology growth (+176% YoY), sustained high gross margins (~70.5%), GAAP profitability, and a large cash balance ($549M). Management highlighted multiple product launches, supportive clinical data (NorthStar Response publication), low QC failure rates, and investments to scale commercial and lab capacity. Principal near-term headwinds are timing-related: reduced true-up revenue in the quarter, >$10M of claims held pending payer in‑network implementation, elevated operating expense from hiring and R&D, and potential short-term gross margin variability as oncology mix shifts. Given the strength of growth, profitability, product momentum and balance sheet versus the described timing and execution risks, the positives materially outweigh the negatives.View all BLLN earnings summariesBLLN Stock 12 Month Forecast
Average Price Target
$123.33
▲(23.23% Upside)
Ownership Overview
7.05% Insiders
6.51% Mutual Funds
16.58% Other Institutional Investors
65.51% Public Companies and
Individual Investors